SequelSEC

SELLAS Life Sciences Group, Inc. SLS

Pharmaceutical Preparations · CIK 0001390478 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$10.63M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

SELLAS Life Sciences Group, Inc. (SLS) reported net income of -$9.60M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from SELLAS Life Sciences Group, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

SELLAS Life Sciences Group, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-31
RevenueUnavailableUnavailable$0$0$0$0$0$0$0$1.00M
Cost of revenueUnavailable$0$0$0$0$0$0$0$0$100.00K
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$0$900.00K
Operating income-$10.63M-$6.87M-$8.18M-$9.36M-$9.05M-$11.28M-$9.45M-$7.15M-$8.62M-$16.74M
Net income-$9.60M-$6.60M-$8.14M-$9.27M-$8.84M-$11.10M-$9.12M-$7.02M-$8.41M-$16.74M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 189.18Mshares 98.56MUnavailableshares 28.36Mshares 28.35Mshares 23.55MUnavailableshares 20.56Mshares 20.29Mshares 15.90M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-0.05$-0.07Unavailable$-0.33$-0.31$-0.47Unavailable$-0.34$-0.41$-1.05
Selling, general & administrativeUnavailable$3.00M$3.08M$3.55M$3.13M$4.11M$3.60M$2.86M$3.09M$3.02M
General & administrative$4.36M$3.00MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

SELLAS Life Sciences Group, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-31
Cash & equivalents$138.34M$25.30M$2.53M$3.97M$13.81M$23.90M$17.12M$21.35M$26.99M$14.25M
Total assets$145.38M$32.30M$6.22M$8.09M$18.57M$29.10M$20.94M$26.00M$32.21M$21.43M
Current assets$142.50M$29.45M$3.17M$5.20M$15.58M$26.02M$17.76M$22.60M$28.74M$17.84M
Total liabilities$7.73M$6.16M$14.20M$11.91M$13.72M$15.94M$16.09M$13.40M$13.15M$17.41M
Current liabilities$7.57M$6.00M$13.74M$11.74M$13.42M$15.51M$15.52M$12.55M$12.19M$10.68M
Total equity incl. NCI$137.66M$26.15M-$7.98M-$3.83M$4.84M$13.17M$4.85M$12.60M$19.06M$4.02M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$1.00M
Goodwill$1.91M$1.91M$1.91M$1.91M$1.91M$1.91M$1.91M$1.91M$1.91M$1.91M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.09M$3.34M$5.64M$4.34M$3.73M$3.10M$3.36M$2.13M$3.34M$2.84M

Cash flow

SELLAS Life Sciences Group, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-31
Operating cash flowUnavailableUnavailable-$4.82M-$6.89M-$7.57M-$12.13M-$5.15M-$5.75M-$5.76M-$7.15M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flowUnavailableUnavailable$0-$3.00MUnavailableUnavailable$0$0UnavailableUnavailable
Financing cash flowUnavailableUnavailable$3.39M$54.00K-$29.00K$18.90M$929.00K$107.00K$23.00M$47.00K
Net change in cashUnavailableUnavailable-$1.44M-$9.84M-$10.10M$6.78M-$4.22M-$5.64M$12.74M-$7.10M
Stock-based compensationUnavailableUnavailable$497.00K$543.00K$514.00K$540.00K$446.00K$455.00K$450.00K$375.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

SELLAS Life Sciences Group, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302025-06-302023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable90.0%
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-1673.5%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable37.5%
Current ratio18.83x4.91x0.23x0.44x1.16x1.68x1.14x1.80x2.36x1.67x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailable-100.0%UnavailableUnavailable-100.0%-82.5%
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-1674.4%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SLS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-19View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

Reconciliation checks needing review

4 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2023-12-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-09-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-03-31

Withheld: gross profit could not be reconciled with the rest of this filer’s statement.